Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Market Overview of Cancer API Market Clinical Trials Review, 2022

Market research future has a cooked research report on analysis of the market structure along with forecast for the next seven years
diksha pote | 12.09.2018
Cancer API Market - Highlights

The manufacturing industry for pharmaceutical small molecule API is presently undergoing a period of swift change. Market reports linked to the healthcare sector made available by Market Research Future along with published reports on other sectors have been recently published along with a report on this industry. The market is projected to achieve high revenue levels while growing with an accelerated CAGR rate in the forecast period.

Request for Sample Report at

Due to the substantial progress in small molecule API manufacturing in segments such as oncology, the market is growing significantly. The market is also significantly benefitted by the surge in the number of contract manufacturers that can manufacture API small molecule products. Moreover, as contract manufacturers focus on the progress and production of small molecule APIs, they are undergoing substantial development. The focus on recombinant proteins and monoclonal antibodies is expected to emerge as a major driver for the growth of the market in the forecast period.

Top Players:




Bristol-Myers Squibb

And more.

Segmental Analysis:

The segmentation of the cancer API market is carried out on the basis of Lisib, Parib, Tinib, Rafenib, Ciclib, and Degib. In the Tinib segment, the molecules involved are Ruxolitinib, Ponatinib, Erlotinib, Alectinib, Osimertinib, Afatinib, Bosutinib, Axitinib, Ceritinib, Acalabrutinib, Sunitinib, Lenvatinib, Brigatinib, Imatinib, Neratinib, Lapatinib, Crizotinib, Cabozantinib, Ibrutinib, Dasatinib, and Gefitinib. In the segment of Rafenib, the molecules contain of Vemurafenib, Dabrafenib, Sorafenib, and Regorafenib, Enasidenib. Under Parib segment the molecules involved are Olaparib, Rucaparib, and Niraparib. Under the Lisib segment molecules, specifically, Idelalisib and Copanlisib are considered. In the Degib category, two main molecules which are considered which are Sonidegib and Vismodegib. In the Ciclib segment, molecules considered are Palbociclib, Ribociclib, and Abemaciclib.

Ask Any Question at

Detailed Regional Analysis:

The market for cancer API differs depending on different regions and countries the basis of the approval process. The five cancer API category molecules are accepted in the US. For example, Brigatinib which is an oral, small molecule drug. It is well recognized as an Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) reversible dual inhibitor. Brigatinib had been produced by Ariad Pharmaceuticals which is a subsidiary of Takeda Pharmaceutical Company Limited.

The FDA had accepted Brigatinib in April 2017 for the treatment of progressive ALK-positive metastatic non-small cell lung cancer. Takeda also has certified rights for marketing this drug under the brand name “Alunbrig.” Also, Neratinib which is also an oral, small molecule drug, was FDA approved in July 2017 for the management of HER2 breast cancer. Neratinib is also presently under investigation for use in other types of cancers, while in Japan and Europe the endorsement of molecules is in progress.

Major TOC of Cancer API Market Research Report – Forecast to 2023:

1 Introduction

2 Research Methodology

3 Market Dynamics

4 Market Factor Analysis

5 Global Cancer API Market

6 Competitive Landscape

7 Company Profiles

8 List of Tables

9 List of Figures

Check Discount Here at

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.


Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312